Aerosolized dornase alpha (rhDNase) in cystic fibrosis.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Clinical Pharmacy and Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 8847368
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Recombinant Human DNase Therapy on Healthcare use and Costs in Patients with Cystic Fibrosis

  1995cited by this paper
• Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

  1994cited by this paper
• Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

  1993cited by this paper
• Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.

  1993cited by this paper
• A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.

  1992cited by this paper
• Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.

  1992cited by this paper
• The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum.

  1990cited by this paper
• Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

  1990cited by this paper
• Gentamicin inactivation in purulent exudates: role of cell lysis.

  1980cited by this paper
• Pus, deoxyribonucleic acid, and sputum viscosity.

  1978cited by this paper
• Studies on pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy.

  1969cited by this paper
• Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions.

  1965cited by this paper
• STUDIES ON PULMONARY SECRETIONS. I. THE OVER-ALL CHEMICAL COMPOSITION OF PULMONARY SECRETIONS FROM PATIENTS WITH CYSTIC FIBROSIS, BRONCHIECTASIS, AND LARYNGECTOMY.

  1963cited by this paper
• Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis.

  1959cited by this paper

• Going the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children

  2022cites this paper
• New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients.

  2013cites this paper
• Method to Introduce Mannitol Powder to Intubated Patients to Improve Sputum Clearance

  2010cites this paper
• Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis

  2009cites this paper
• DNA Quantification and Fragmentation in Sputum after Inhalation of Recombinant Human Deoxyribonuclease

  2008cites this paper
• Determination of Pulmozyme (dornase alpha) stability using a kinetic colorimetric DNase I activity assay.

  2006cites this paper
• Recombinant proteins for genetic disease

  1999cites this paper